Trelagliptin

DPP-4 inhibitor,long-acting and selective CAS# 865759-25-7

Trelagliptin

Catalog No. BCC2014----Order now to get a substantial discount!

Product Name & Size Price Stock
Trelagliptin: 5mg $92 In Stock
Trelagliptin: 10mg Please Inquire In Stock
Trelagliptin: 20mg Please Inquire Please Inquire
Trelagliptin: 50mg Please Inquire Please Inquire
Trelagliptin: 100mg Please Inquire Please Inquire
Trelagliptin: 200mg Please Inquire Please Inquire
Trelagliptin: 500mg Please Inquire Please Inquire
Trelagliptin: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Trelagliptin

Number of papers citing our products

Chemical structure

Trelagliptin

3D structure

Chemical Properties of Trelagliptin

Cas No. 865759-25-7 SDF Download SDF
PubChem ID 15983988 Appearance Powder
Formula C18H20FN5O2 M.Wt 357.38
Type of Compound N/A Storage Desiccate at -20°C
Synonyms SYR-472
Solubility DMSO : ≥ 50 mg/mL (139.91 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
SMILES CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N
Standard InChIKey IWYJYHUNXVAVAA-OAHLLOKOSA-N
Standard InChI InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Trelagliptin

DescriptionTrelagliptin is a long acting inhibitor of dipeptidyl peptidase-4 (DPP-4).
TargetsDPP-4    

Trelagliptin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Trelagliptin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Trelagliptin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7981 mL 13.9907 mL 27.9814 mL 55.9628 mL 69.9536 mL
5 mM 0.5596 mL 2.7981 mL 5.5963 mL 11.1926 mL 13.9907 mL
10 mM 0.2798 mL 1.3991 mL 2.7981 mL 5.5963 mL 6.9954 mL
50 mM 0.056 mL 0.2798 mL 0.5596 mL 1.1193 mL 1.3991 mL
100 mM 0.028 mL 0.1399 mL 0.2798 mL 0.5596 mL 0.6995 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Trelagliptin

Trelagliptin (SYR-472) is a selective inhibitor of DPP-4 and is developed for the treatment of type 2 diabetes mellitus (T2DM) [1].

Dipeptidyl peptidase (DPP)-4 also known as adenosine deaminase complexing protein 2 or CD26 is an antigenic enzyme that expressed on the surface of most cell types and plays an important role in regulating immune system, signal transduction and apoptosis [2, 3].

Trelagliptin (SYR-472) is a potent DPP-4 inhibitor and can be administered once weekly which unlike its other class approved agents that be taken once daily [1]. In Japan, clinical trials had been conducted to detect the effectiveness of Trelagliptin by comparing with the approved medicine—alogliptin and it was shown that Trelagliptin once-weekly exhibited similar efficacy and safety to alogliptin once daily, which indicated that Trelagliptin could be a useful new antidiabetes drug that needs to be given once a week [2].

Trelagliptin (SYR-472) has been used in phase 2 and phase 3 clinical trials for the treatment of patients with T2DM showed similar efficacy and safety to alogliptin once daily and produced clinically and statistically significant improvements in glycaemic control with well tolerated in Japan [2, 3].

References:
[1].  McKeage, K., Trelagliptin: First Global Approval. Drugs, 2015. 75(10): p. 1161-4.
[2].  Inagaki, N., et al., Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol, 2015. 3(3): p. 191-7.
[3].  Inagaki, N., et al., SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol, 2014. 2(2): p. 125-32.

Featured Products
New Products
 

References on Trelagliptin

Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.[Pubmed:27209451]

J Pharm Biomed Anal. 2016 Sep 5;128:18-27.

A sensitive, selective and stability indicating reversed-phase LC method was developed for the determination of process related impurities of Trelagliptin succinate in bulk drug. Six impurities were identified by LC-MS. Further, their structures were characterized and confirmed utilizing LC-MS/MS, IR and NMR spectral data. The most probable mechanisms for the formation of these impurities were also discussed. To the best of our knowledge, six structures among these impurities are new compounds and have not been reported previously. The superior separation was achieved on an InertSustain C18 (250mmx4.6mm, 5mum) column in a gradient mixture of acetonitrile and 20mmol potassium dihydrogen phosphate with 0.25% triethylamine (pH adjusted to 3.5 with phosphate acid). The method was validated as per regulatory guidelines to demonstrate system suitability, specificity, sensitivity, linearity, robustness, and stability.

A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study.[Pubmed:27561183]

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:166-171.

This study aims to develop and validate a simple, rapid and sensitive ultra-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) method for exploring pharmacokinetic characteristics of Trelagliptin. Protein precipitation by acetonitrile was used to prepare plasma sample. A RRHD Eclipse Plus C18 (2.1x50mm, 1.8mu) column with gradient mobile phase (containing acetonitrile and 0.1% formic acid) help to achieve the separation of Trelagliptin and carbamazepine (IS) with high selectivity. Detection of target fragment ions m/z 358.2-->133.9 for Trelagliptin, and m/z 237.1-->194.0 for IS was performed in positive-ion electrospray ionization mass spectrometry by multiple reaction monitoring. Linear calibration plots were achieved in the range of 5-4000ng/mL for Trelagliptin (R(2)=0.999) in rat plasma. The recovery of Trelagliptin ranged from 87.8% to 93.7%. The method was showed to be accurate, precise and stable. No obvious matrix effect was found. It has been fully validated and successfully applied to pharmacokinetic study of Trelagliptin.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.[Pubmed:27328054]

PLoS One. 2016 Jun 21;11(6):e0157509.

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of Trelagliptin, which exhibited approximately 4- and 12-fold more potent inhibition against human dipeptidyl peptidase-4 than alogliptin and sitagliptin, respectively, and >10,000-fold selectivity over related proteases including dipeptidyl peptidase-8 and dipeptidyl peptidase-9. Kinetic analysis revealed reversible, competitive and slow-binding inhibition of dipeptidyl peptidase-4 by Trelagliptin (t1/2 for dissociation approximately 30 minutes). X-ray diffraction data indicated a non-covalent interaction between dipeptidyl peptidase and Trelagliptin. Taken together, potent dipeptidyl peptidase inhibition may partially contribute to sustained efficacy of Trelagliptin.

Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.[Pubmed:27809903]

Cardiovasc Diabetol. 2016 Nov 4;15(1):153.

BACKGROUND: Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of Trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of Trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators. METHODS: This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20-74 years, who visited our outpatient department. The patients were treated with Trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period. RESULTS: A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 +/- 2.7% at baseline vs. 2.66 +/- 3.8% post-treatment, P = 0.785) and ADMA (0.41 +/- 0.0 microg/mL at baseline vs. 0.40 +/- 0.0 microg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 +/- 6.9 microg/mL at baseline vs. 8.82 +/- 8.3 microg/mL post-treatment, P < 0.002). CONCLUSIONS: In this pilot study, Trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that Trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311).

Description

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).

Keywords:

Trelagliptin,865759-25-7,SYR-472,Natural Products,DPP-4, buy Trelagliptin , Trelagliptin supplier , purchase Trelagliptin , Trelagliptin cost , Trelagliptin manufacturer , order Trelagliptin , high purity Trelagliptin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: